Response And Tolerability Of Sofosbuvir Plus Daclatasvir In Elderly Patients With Chronic Hepatitis-C.
Aged
Aged, 80 and over
Antiviral Agents
/ adverse effects
Carbamates
Drug Therapy, Combination
Female
Hepacivirus
Hepatitis C, Chronic
/ drug therapy
Humans
Imidazoles
/ adverse effects
Male
Middle Aged
Prospective Studies
Pyrrolidines
Sofosbuvir
/ adverse effects
Sustained Virologic Response
Valine
/ analogs & derivatives
Chronic hepatitis C; Sofosbuvir; Daclatasvir
Cirrhosis; Sustained virological
response
Elderly patients
Journal
Journal of Ayub Medical College, Abbottabad : JAMC
ISSN: 1819-2718
Titre abrégé: J Ayub Med Coll Abbottabad
Pays: Pakistan
ID NLM: 8910750
Informations de publication
Date de publication:
Historique:
entrez:
15
1
2020
pubmed:
15
1
2020
medline:
17
4
2020
Statut:
ppublish
Résumé
The approval of direct acting anti-viral drugs has expanded the treatment access to all patient populations including elderly patients, who were previously neglected. We evaluated the response and tolerability of sofosbuvir plus daclatasvir in old age patients >60 year infected with HCV. In this prospective observational study, 100 patients were enrolled and were divided into two groups: aged 60-69 (group A) and aged 70 and older (group B). All the patients were given sofosbuvir plus daclatasvir. Sustained virologic response at 12 weeks was the primary endpoint. Response and tolerability of treatment were analysed and compared between these patient groups. Hundred patients aged ≥60 years were treated with sofosbuvir plus daclatasvir. Sustained virologic response rate was 91% in group A (aged 60- 69 year) and 87.8% in group B (aged 70 year and older). No significant adverse effect was noted in both groups. No treatment discontinuation was encountered. Direct acting antiviral drug therapy is highly efficacious and safe for the treatment of HCV in older adults.
Sections du résumé
BACKGROUND
BACKGROUND
The approval of direct acting anti-viral drugs has expanded the treatment access to all patient populations including elderly patients, who were previously neglected. We evaluated the response and tolerability of sofosbuvir plus daclatasvir in old age patients >60 year infected with HCV.
METHODS
METHODS
In this prospective observational study, 100 patients were enrolled and were divided into two groups: aged 60-69 (group A) and aged 70 and older (group B). All the patients were given sofosbuvir plus daclatasvir. Sustained virologic response at 12 weeks was the primary endpoint. Response and tolerability of treatment were analysed and compared between these patient groups.
RESULTS
RESULTS
Hundred patients aged ≥60 years were treated with sofosbuvir plus daclatasvir. Sustained virologic response rate was 91% in group A (aged 60- 69 year) and 87.8% in group B (aged 70 year and older). No significant adverse effect was noted in both groups. No treatment discontinuation was encountered.
CONCLUSIONS
CONCLUSIONS
Direct acting antiviral drug therapy is highly efficacious and safe for the treatment of HCV in older adults.
Substances chimiques
Antiviral Agents
0
Carbamates
0
Imidazoles
0
Pyrrolidines
0
Valine
HG18B9YRS7
daclatasvir
LI2427F9CI
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM